Conditions: Autosomal Dominant Polycystic Kidney Disease
Keywords: ADPKD Tolvaptan
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

Detailed description:
Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

Arms:
arm 1: None

Interventions: intervention 1: OPC-41061
Intervention descriptions: intervention 1: orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.

Protocol document: